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PART I: INTRODUCTION 
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During the last decade, congestive heart failure has evolved 
into the most important public health problem in cardiovas- 
cular medicine. It is estimated that heart failure aiIlicts more 
than 3 million patients in the United States-nearly 1.5% of 
the adult population. The disease is at preseut the nation’ : 
most rapidly growing cardiovascular disorder; almost 
400,000 people develop heart failure for the 6rst time each 
year. Heart failure is a major cause of disability and morbid- 
ity. It impairs the ability of patients to carry out activities of 
daily living, care for themselves and support their families. 
In addition, it is responsible for the hospital admission of 
nearly 1 million Americans annually and is the most common 
reason for hospitalization f the elderly. Heart failure is a 
major contributor to the cost of health care-tbe wuntry 
spends more than $8 billion in the care of these patients 
annually. Finally, it is a @or cause of cardiovascular death; 
nearly 200,OllO patients in the U.S. die of heart failure each 
year. 
Given the enormous importance ofheart failure, it would 
seem appropriate to channel considerable public and private 
resources to the conquest of this disease. Yet, to do so 
effectively, it is critical to review what we know and what we 
need to do. Such a review is particularly important today 
because our perspective of and our approach to the syn- 
drome has undergone dramatic hanges in recent years (1). 
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Evolution of the Syndrome of Heart Failure 
Heart failwe in the 1990s is fundamentally a different 
disorder f om what it was during most of this century. Thirty 
to 50 years ago, the most frequent causes of chronic heart 
failure were hypertensive h art disease and valvular heart 
disease, particularly mitral stenosis. At that ime, physicians 
viewed heart Ghrre as a slowly progressive disorder that 
remained compensated formany years. The major challenge 
for physicians was the control of pulmonary and peripheral 
edema, and numerous interventions were developed to de 
plete the body of excess fluid. In addition, many patients 
with heart failure had arrhythmias, which generally origi- 
nated in the atria. It is noteworthy that digitalis gained 
popularity inthe treatment of heart failure in part because of 
its ability to control the ventricular response to these ar- 
rhythmias (2). Yet despite the control of fluid retention and 
heart rate, heart failure progressed and the patient eveatu- 
ally died. The cause of death was commonly a pulmonary or 
cutanwus infection that resulted from intetference with 
local defense mechanisms overwhelmed bythe presence of 
edema. 
This perspective of heart failure differs markedly from the 
syndrome of hti: failure in the 1990s. Left ventricular 
dysfunction due to wronary artery disease isnow the most 
common cause of chronic heart failure. Heart failure may 
evolve rapidly atter the loss of a critical quantity of myocar- 
dium a$ the diit result of ischemic necrosis or it may 
develop gradually as a consequence of ventricular remodel- 
ing that follows a large myocardial infarction. In addition, 
heart failure may occur as the result of a dilated cardiomy- 
opathy, the prevalence of which has increased during the last 
20 years. In the 199Os, the major therapeutic challenge for 
the physician is no longer the wntrol of fluid retention, 
becausewith the advent of potent diuretic drugs-most 
patients with advanced symptoms do not have reIiactorY 
edema. Now physicians direct heir therapeutic efforts to the 
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amelioration f effort intolerance (precipitated byactivities 
of daily living) and the reduction of cardiovascular morbidity 
and mortality. Arrhythmias re still common i  patients with 
heart failure, but these generalIy originate in the ventricles 
rather than the atria. Finally, the course of heart failure does 
not progress predictably from mild to severe disease, unfold- 
ing over a period of decades. Instead, advanced symptoms 
can develop in a matter of weeks or months (rather than 
years or decades), and sudden death may interrupt he 
course of the disease at any time. 
Evolution of New Pathophysiologic Concepts 
of Heart Failure 
As the syndrome of heart failure has evolved during 
recent decades, o has our understanding of the pathophys- 
iology of heart failure. Thirty years ago, physicians believed 
that endogenous mechanisms activated during the course of 
heart failure played an inrportant adaptive role in supporting 
the circulation as heart failure progressed. According to this 
traditional view, systemic vasoconstriction occurred in pa- 
tients with heart failure to support he perfusion of vital 
organs; pulmonary vasoconstriction developed to reduce the 
rate of blood flow into the left heart chambers and thus lower 
puhnonary venous pressures; and the sympathetic nervous 
system was activated toenhance card& contractility. Phy 
sicians were advised not to interfere with these ndogenous 
compensatory mechanisms because such interference would 
produce deleterious hemodynamic and clinical effects (3). 
Our view of the pathophysiology of heart failure has 
changed ramatically during the last 20 years. We now 
believe that systemic vasoconstriction can limit the systolic 
performance of the left ventricle and contribute to the 
development of heart failure. We believe that neurohor- 
monal activation accelerates the rate of progression ofheart 
failure, not only because of its ability to cause systemic 
vasoconstriction but because such activation leads to direct 
deleterious effects on the heart. This shirt in our view of the 
pathophysiolqy ofheart failure-from the original concept 
that endogenous mechanisms were adaptive to the present 
concept hat such mechanisms are detrimental-has been 
supported by the results of cliical studies. Pharmacologic 
blockade of the alpha-adrenergic and angiotensin II recep- 
tors produces notable short-term hemodynamic benefits 
(4,5). Sustained intetieren<e with endogenous neurohor- 
mortal systems (produced by inhibition of the angiotensin- 
converting enzyme or blockade of the beta-adrenergic ecep- 
tor) produces long-term symptomatic improvement (6,7). 
Finally, the long-term administration f vasodilators and 
converting enzyme inhibitors reduces morbidity and mortal- 
ity (8,9). These (and many other) studies have proved 
conclusively that he activation ofendogenous vasoconstric- 
tar and neurohormonal mechanisms in heart failure can no 
longer be regarded as a beneficial homeostatic process. 
The Development and Assessment of New 
Therapeutic Interventions 
Changes in the clinical features and pathophysiology of 
heart failure during the last 20 years have been paralleled by 
a dramatic ncrease in the number of therapeutic strategies, 
many of which have challenged traditional pproaches to
management. Whereas in the past, physicians believed that 
bed rest was an important ingredient inthe recovery of the 
patient with heart failure, we now encourage exercise to 
minimize the magnitude ofdeconditioning. Whereas in the 
past, physicians believed that systemic perfusion pressures 
had to be supported to preserve organ function, we now 
routinely decrease blood pressure with potent vasodilator 
drugs. Whereas in the past, physicians thought hat the 
administration f inotropic drugs would address the funda- 
mental defect in heart failure, we now worry about the 
long-term safety of inotropic agents (10) and even consider 
treating patients with drugs that depress the function of the 
heart (e.g., beta-blockers). 
These advances intherapeutics have been paralleled by 
major advances in our ability to assess the eIllcacy and 
safety of new interventions. Twenty years ago, physicians 
believed that hey could evaluate the utility of a new drug by 
measuring the change its administration produced tin the 
symptoms and clinical status of a few patients. In the 1970s 
and MOs, these subjective assessments were supplemented 
by objective measurements of left ventricular function, 
assessed using either invasive or noninvasive t chniques. 
However, during the last decade, we have learned that such 
assessments can be misleading. Changes in symptoms in a 
small number of patients can be produced by placebo 
therapy, and changes in ventricular function (even if pro- 
duced by a drug) do not reliably predict changes in the 
clinical status or outcome of patients. In the 19!3Os and 199Os, 
we have learned that interpretable information concerning 
the efficacy and safety of therapeutic interventions can be 
most readily obtained by performing large scale controlled 
clinical trials that evaluate clinically relevant endpoints. 
Aim of the Supplement 
Given these xtraordinary changes in our perspective of
heart faiiure during the last 20 years, it is appiopriate ‘fi 
assess where we are and where we need to go. This is a 
particular appropriate ime to do so because the recent 
completion of several large scale multicenter trials (8-14) 
has brought considerable n w knowledge tothe arca of heart 
failure. These trials have aflirmed the changes in clinical 
features and natural history of heart failure that have OQ 
curred uring the last 20 years and have demonstrated the 
utility of interventions that have challenged traditional con- 
cepts of pathophysiology and therapeutics. Yet these trials 
have also shown us that, despite the optimal management, 
heart failure remains a disabling and lethai disease. Fortu- 
nately, we are better equipped than ever to meet this 
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challenge ofheart failure with the development of new tools 
of molecular biology and experimental physiology. 
The aim of this supplement tothe Journal ofthe Ameri- 
can College of Cardiology is to provide a comprehensive 
review of our present knowledge ofthe pathophysiology and 
treatment of chronic heart failure. Whereas other supplements 
have focused on specific aspects of the disorder or a specific 
approach to management, the present collection of manu- 
scripts is intended topresent a comprehensive o rview of the 
syndrome. The articles in this supplement represent the pm 
ceedings ofa 2day symposium that was held on April 26 and 
27,1992 under the sponsorship ofthe Clinical Trials Branch of 
the National Heart, Lung, and Blood Institute. All articles in 
the supplement have undergone peer review. Two reports 
presented at the meeting have been published elsewhere 
(14,15) and are not reproduced in this supplement. Readers are 
referred to the primary publications for information regarding 
these presentations. 
The editors give special thanks to Jeanette Duggan for her 
time, effort and administrative management of he workshop 
and supplement. In addition, we are grateful to all of the 
speakers and participants for their active involvement i  this 
meeting and to the sponsors for their support of the supple- 
ment. publication fthese proceedings has been made possible 
by grants from several pharmaceutical ompanies, none of 
which played any role in the selection ofparticipants or topics. 
It is through such efforts that combine the talents and resources 
of government, industry and academic medicine that he chal- 
lenge of heart failure will be successfidly met. 
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